IS2994B - Fosfónöt, monofosfónamidöt, bisfosfónamidöt til meðhöndlunar á veirusjúkdómum - Google Patents

Fosfónöt, monofosfónamidöt, bisfosfónamidöt til meðhöndlunar á veirusjúkdómum

Info

Publication number: IS2994B
Authority: IS; Iceland
Prior art keywords: monophosphonamides; bisphosphonamides; phosphonates; treatment; viral diseases
Prior art date: 2003-12-30

Application number

IS8516A

Other languages

English (en)

Other versions

IS8516A (is

Inventor

Cheng Xiaqin

P. Cook Gary

C. Desai Manoj

Doerffler Edward

He Gong-Xin

U. Kim Choung

A. Lee William

C. Rohloff John

Wang Jianying

Yang Zheng-Yu

Original Assignee

Gilead Sciences, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-12-30

Filing date

2006-06-21

Publication date

2018-03-15

2006-06-21 Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.

2006-06-21 Publication of IS8516A publication Critical patent/IS8516A/is

2018-03-15 Publication of IS2994B publication Critical patent/IS2994B/is

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/44—Amides thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/664—Amides of phosphorus acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

IS8516A 2003-12-30 2006-06-21 Fosfónöt, monofosfónamidöt, bisfosfónamidöt til meðhöndlunar á veirusjúkdómum IS2994B (is)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US53374503P	2003-12-30	2003-12-30
US59098704P	2004-07-26	2004-07-26
US60659504P	2004-09-01	2004-09-01
PCT/US2004/043969 WO2005066189A1 (en)	2003-12-30	2004-12-29	Phosphonates, monophosphonamidates, bisphosphonamidates for the treatment of viral diseases

Publications (2)

Publication Number	Publication Date
IS8516A IS8516A (is)	2006-06-21
IS2994B true IS2994B (is)	2018-03-15

Family

ID=34753695

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS8516A IS2994B (is)	2003-12-30	2006-06-21	Fosfónöt, monofosfónamidöt, bisfosfónamidöt til meðhöndlunar á veirusjúkdómum

Country Status (27)

Country	Link
US (5)	US7553825B2 (is)
EP (2)	EP1716162B1 (is)
JP (2)	JP4949852B2 (is)
KR (2)	KR20120080240A (is)
CN (2)	CN101816664B (is)
AP (1)	AP2212A (is)
AT (1)	ATE478082T1 (is)
AU (2)	AU2004312546B2 (is)
BR (1)	BRPI0418251C1 (is)
CA (1)	CA2550222C (is)
CY (2)	CY1111050T1 (is)
DE (1)	DE602004028763D1 (is)
DK (2)	DK2204374T3 (is)
EA (1)	EA011304B1 (is)
ES (2)	ES2389602T3 (is)
HR (3)	HRP20060254A2 (is)
IL (1)	IL176407A (is)
IS (1)	IS2994B (is)
NO (2)	NO338001B1 (is)
NZ (1)	NZ548771A (is)
PL (3)	PL1716162T3 (is)
PT (2)	PT1716162E (is)
RS (2)	RS51476B (is)
SG (1)	SG149075A1 (is)
SI (2)	SI2204374T1 (is)
WO (1)	WO2005066189A1 (is)
ZA (1)	ZA200606049B (is)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8512718B2 (en)	2000-07-03	2013-08-20	Foamix Ltd.	Pharmaceutical composition for topical application
IL164809A0 (en) *	2002-05-13	2005-12-18	Metabasis Therapeutics Inc	Novel phosphonic acid basdrugs of pmea and its analogues
JP4332496B2 (ja)	2002-05-13	2009-09-16	メタバシス・セラピューティクス・インコーポレイテッド	Ｐｍｅａおよびｐｍｐａ環生成合成
IL152486A0 (en)	2002-10-25	2003-05-29	Meir Eini	Alcohol-free cosmetic and pharmaceutical foam carrier
US8900554B2 (en)	2002-10-25	2014-12-02	Foamix Pharmaceuticals Ltd.	Foamable composition and uses thereof
US9668972B2 (en)	2002-10-25	2017-06-06	Foamix Pharmaceuticals Ltd.	Nonsteroidal immunomodulating kit and composition and uses thereof
US7704518B2 (en)	2003-08-04	2010-04-27	Foamix, Ltd.	Foamable vehicle and pharmaceutical compositions thereof
US8486376B2 (en)	2002-10-25	2013-07-16	Foamix Ltd.	Moisturizing foam containing lanolin
US7820145B2 (en)	2003-08-04	2010-10-26	Foamix Ltd.	Oleaginous pharmaceutical and cosmetic foam
US9211259B2 (en)	2002-11-29	2015-12-15	Foamix Pharmaceuticals Ltd.	Antibiotic kit and composition and uses thereof
US20080138296A1 (en)	2002-10-25	2008-06-12	Foamix Ltd.	Foam prepared from nanoemulsions and uses
US7700076B2 (en)	2002-10-25	2010-04-20	Foamix, Ltd.	Penetrating pharmaceutical foam
US9265725B2 (en)	2002-10-25	2016-02-23	Foamix Pharmaceuticals Ltd.	Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US10117812B2 (en)	2002-10-25	2018-11-06	Foamix Pharmaceuticals Ltd.	Foamable composition combining a polar solvent and a hydrophobic carrier
US8119109B2 (en)	2002-10-25	2012-02-21	Foamix Ltd.	Foamable compositions, kits and methods for hyperhidrosis
US8119150B2 (en)	2002-10-25	2012-02-21	Foamix Ltd.	Non-flammable insecticide composition and uses thereof
ES2532906T5 (es)	2002-10-25	2022-03-23	Foamix Pharmaceuticals Ltd	Espuma cosmética y farmacéutica
US7575739B2 (en)	2003-04-28	2009-08-18	Foamix Ltd.	Foamable iodine composition
US8795693B2 (en)	2003-08-04	2014-08-05	Foamix Ltd.	Compositions with modulating agents
US8486374B2 (en)	2003-08-04	2013-07-16	Foamix Ltd.	Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
WO2005066189A1 (en) *	2003-12-30	2005-07-21	Gilead Sciences, Inc.	Phosphonates, monophosphonamidates, bisphosphonamidates for the treatment of viral diseases
RU2006138907A (ru) *	2004-06-08	2008-07-20	Метабазис Терапеутикс	Синтез сложных циклических эфиров с применением кислоты льюиса
WO2007002808A1 (en) *	2005-06-29	2007-01-04	Gilead Sciences, Inc.	Anti-nonmelanoma carcinoma compounds, compositions, and methods of use thereof
WO2007002912A2 (en) *	2005-06-29	2007-01-04	Gilead Sciences, Inc.	Anti-proliferative compounds, compositions, and methods of use thereof
CN101442994B (zh) *	2006-05-16	2013-03-06	吉里德科学公司	用于治疗恶性血液病的方法和组合物
WO2007137196A2 (en) *	2006-05-19	2007-11-29	Threshold Pharmaceuticals, Inc.	Tubulin binding anti cancer compounds and prodrugs thereof
US8338593B2 (en) *	2006-07-07	2012-12-25	Gilead Sciences, Inc.	Modulators of toll-like receptor 7
EP2046121B1 (en) *	2006-07-14	2012-08-22	Stiefel Research Australia Pty Ltd	Fatty acid pharmaceutical foam
US20080260655A1 (en)	2006-11-14	2008-10-23	Dov Tamarkin	Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8636982B2 (en)	2007-08-07	2014-01-28	Foamix Ltd.	Wax foamable vehicle and pharmaceutical compositions thereof
WO2009069006A2 (en)	2007-11-30	2009-06-04	Foamix Ltd.	Foam containing benzoyl peroxide
US8518376B2 (en)	2007-12-07	2013-08-27	Foamix Ltd.	Oil-based foamable carriers and formulations
WO2009090495A2 (en)	2007-12-07	2009-07-23	Foamix Ltd.	Oil and liquid silicone foamable carriers and formulations
CA2712120A1 (en)	2008-01-14	2009-07-23	Foamix Ltd.	Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
TWI444384B (zh)	2008-02-20	2014-07-11	Gilead Sciences Inc	核苷酸類似物及其在治療惡性腫瘤上的用途
US20120087872A1 (en)	2009-04-28	2012-04-12	Foamix Ltd.	Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof
WO2011013008A2 (en)	2009-07-29	2011-02-03	Foamix Ltd.	Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
CA2769625C (en)	2009-07-29	2017-04-11	Foamix Ltd.	Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9849142B2 (en)	2009-10-02	2017-12-26	Foamix Pharmaceuticals Ltd.	Methods for accelerated return of skin integrity and for the treatment of impetigo
WO2011039637A2 (en)	2009-10-02	2011-04-07	Foamix Ltd.	Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
CN102309984B (zh) *	2011-07-22	2013-05-01	华东师范大学	一种磷酸酰胺类双功能催化剂及其合成方法
US9593137B2 (en)	2011-12-22	2017-03-14	Geron Corporation	Guanine analogs as telomerase substrates and telomere length affectors
CN103665043B (zh)	2012-08-30	2017-11-10	江苏豪森药业集团有限公司	一种替诺福韦前药及其在医药上的应用
JP6462659B2 (ja)	2013-03-15	2019-01-30	ザリージェンツオブザユニバーシティオブカリフォルニア	非環式ヌクレオシドホスホン酸ジエステル
CN104804042B (zh) *	2014-01-24	2018-01-19	齐鲁制药有限公司	核苷酸膦酸酯类化合物、其药物组合物、制备方法及用途
WO2015123352A1 (en)	2014-02-13	2015-08-20	Ligand Pharmaceuticals, Inc.	Prodrug compounds and their uses
CN105531281B (zh) *	2014-04-21	2017-12-15	四川海思科制药有限公司	一种核苷类似物及其中间体的制备方法
US9994600B2 (en)	2014-07-02	2018-06-12	Ligand Pharmaceuticals, Inc.	Prodrug compounds and uses therof
CN112898345A (zh) *	2014-09-15	2021-06-04	加利福尼亚大学董事会	核苷酸类似物
SG11201705069YA (en)	2014-12-26	2017-07-28	Univ Emory	N4-hydroxycytidine and derivatives and anti-viral uses related thereto
WO2016174081A1 (en) *	2015-04-28	2016-11-03	Ku Leuven Research & Development	Novel antiviral compounds, a process for their preparation, and their use for treating viral infections
WO2017007701A1 (en) *	2015-07-07	2017-01-12	Merck Sharp & Dohme Corp.	Antiviral phosphodiamide compounds
TWI620754B (zh) *	2015-08-26	2018-04-11		Method for preparing amino phosphate derivative and preparation method thereof
EP3350191B9 (en)	2015-09-15	2021-12-22	The Regents of the University of California	Nucleotide analogs
WO2017100108A1 (en)	2015-12-10	2017-06-15	Merck Sharp & Dohme Corp.	Antiviral phosphodiamide prodrugs of tenofovir
WO2017106069A1 (en)	2015-12-15	2017-06-22	Merck Sharp & Dohme Corp.	Antiviral oxime phosphoramide compounds
WO2017124896A1 (zh) *	2016-01-19	2017-07-27	四川海思科制药有限公司	一种核苷类似物的磷酰胺酯前药及其应用
US10398641B2 (en)	2016-09-08	2019-09-03	Foamix Pharmaceuticals Ltd.	Compositions and methods for treating rosacea and acne
CN108137630A (zh) *	2016-09-23	2018-06-08	鲁汶天主教大学	氟化无环核苷膦酸酯的前药
EP3532069A4 (en)	2016-10-26	2020-05-13	Merck Sharp & Dohme Corp.	ANTIVIRAL ARYL AMID PHOSPHODIAMID COMPOUNDS
BR112019013017A2 (pt)	2016-12-22	2020-01-14	Idenix Pharmaceuticals Llc	compostos de éster alifático antiviral de tenofovir ou sais farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e uso dos mesmos
MA47131A (fr) *	2016-12-22	2021-05-12	Idenix Pharmaceuticals Llc	Composés benzyl-amide phosphodiamide antiviraux
CN108276444A (zh) *	2017-01-06	2018-07-13	米文君	一类新的化合物及其用途
US20190374557A1 (en) *	2017-02-28	2019-12-12	Alexandre Vasilievich Ivachtchenko	Cyclobutyl (S)-2-[[[(R)-2-(6-aminopurin-9-yl)-1-methyl-ethoxy]methyl-phenoxy-phosphoryl]amino]-propanoates, and production process and application thereof
PL3706762T3 (pl)	2017-12-07	2025-02-10	Emory University	N4-hydroksycytydyna i pochodne oraz związane z nimi zastosowania przeciwwirusowe
AU2019207625A1 (en)	2018-01-09	2020-07-30	Ligand Pharmaceuticals, Inc.	Acetal compounds and therapeutic uses thereof
US11826375B2 (en)	2018-07-19	2023-11-28	Merck Sharp & Dohme Llc	Phosphinic amide prodrugs of tenofovir
KR102710881B1 (ko) *	2018-09-28	2024-09-26	고에이 가가쿠 가부시키가이샤	아미데이트 화합물의 제조 방법 및 아미데이트 화합물
WO2021202669A2 (en)	2020-04-01	2021-10-07	Reyoung Corporation	Nucleoside and nucleotide conjugate compounds and uses thereof
US12110305B2 (en)	2020-08-07	2024-10-08	Gilead Sciences, Inc.	Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
CA3262284A1 (en)	2022-07-21	2024-01-25	Antiva Biosciences Inc	Pharmaceutical compositions and forms for the treatment of human papillomavirus (HPV) infection and HPV-induced neoplasm
CN118652276B (zh) *	2024-08-19	2024-10-15	成都工业学院	一种用于治疗癌症疾病的化合物的制备工艺
CN118652277A (zh) *	2024-08-19	2024-09-17	成都工业学院	一种用于治疗癌症疾病的化合物的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2528490C2 (de) *	1975-06-26	1983-04-28	Henkel KGaA, 4000 Düsseldorf	Verfahren zur Herstellung saurer Protease
US4816570A (en) *	1982-11-30	1989-03-28	The Board Of Regents Of The University Of Texas System	Biologically reversible phosphate and phosphonate protective groups
US4968788A (en)	1986-04-04	1990-11-06	Board Of Regents, The University Of Texas System	Biologically reversible phosphate and phosphonate protective gruops
DE69115694T2 (de)	1990-06-13	1996-10-17	Arnold Newton Mass. Glazier	Phosphorylierte prodrugs
DE10399025I2 (de) *	1990-09-14	2007-11-08	Acad Of Science Czech Republic	Wirkstoffvorläufer von Phosphonaten
US5977061A (en) *	1995-04-21	1999-11-02	Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic	N6 - substituted nucleotide analagues and their use
US6312662B1 (en) *	1998-03-06	2001-11-06	Metabasis Therapeutics, Inc.	Prodrugs phosphorus-containing compounds
US20030072814A1 (en) *	1999-12-16	2003-04-17	Maibach Howard I.	Topical pharmaceutical composition for the treatment of warts
EP1244668B1 (en)	2000-01-07	2006-04-05	Universitaire Instelling Antwerpen	Purine derivatives, process for their preparation and use thereof
EP2682397B1 (en) *	2000-07-21	2017-04-19	Gilead Sciences, Inc.	Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
DE10236294A1 (de) *	2001-08-17	2003-02-27	Alstom Switzerland Ltd	Gasversorgungskontrolleinrichtung einer Gasspeicherkraftanlage
CN1168449C (zh) *	2002-12-23	2004-09-29	梁有国	抗人乳头瘤病毒感染的药物
WO2005066189A1 (en)	2003-12-30	2005-07-21	Gilead Sciences, Inc.	Phosphonates, monophosphonamidates, bisphosphonamidates for the treatment of viral diseases

2004
- 2004-12-29 WO PCT/US2004/043969 patent/WO2005066189A1/en not_active Ceased
- 2004-12-29 DK DK10158740.0T patent/DK2204374T3/da active
- 2004-12-29 US US11/026,303 patent/US7553825B2/en active Active
- 2004-12-29 EP EP04815956A patent/EP1716162B1/en not_active Expired - Lifetime
- 2004-12-29 PL PL04815956T patent/PL1716162T3/pl unknown
- 2004-12-29 ES ES10158740T patent/ES2389602T3/es not_active Expired - Lifetime
- 2004-12-29 DE DE602004028763T patent/DE602004028763D1/de not_active Expired - Lifetime
- 2004-12-29 EA EA200601263A patent/EA011304B1/ru not_active IP Right Cessation
- 2004-12-29 AP AP2006003675A patent/AP2212A/xx active
- 2004-12-29 RS RSP-2010/0490A patent/RS51476B/sr unknown
- 2004-12-29 AT AT04815956T patent/ATE478082T1/de active
- 2004-12-29 PT PT04815956T patent/PT1716162E/pt unknown
- 2004-12-29 HR HR20060254A patent/HRP20060254A2/xx not_active Application Discontinuation
- 2004-12-29 CA CA2550222A patent/CA2550222C/en not_active Expired - Lifetime
- 2004-12-29 ES ES04815956T patent/ES2350983T3/es not_active Expired - Lifetime
- 2004-12-29 PL PL10158740T patent/PL2204374T3/pl unknown
- 2004-12-29 RS RS20120389A patent/RS52433B/sr unknown
- 2004-12-29 CN CN2010101456719A patent/CN101816664B/zh not_active Expired - Lifetime
- 2004-12-29 BR BRPI0418251A patent/BRPI0418251C1/pt not_active IP Right Cessation
- 2004-12-29 SI SI200431910T patent/SI2204374T1/sl unknown
- 2004-12-29 PT PT10158740T patent/PT2204374E/pt unknown
- 2004-12-29 CN CN2004800394690A patent/CN1950383B/zh not_active Expired - Lifetime
- 2004-12-29 NZ NZ548771A patent/NZ548771A/en not_active IP Right Cessation
- 2004-12-29 DK DK04815956.0T patent/DK1716162T3/da active
- 2004-12-29 SG SG200809660-4A patent/SG149075A1/en unknown
- 2004-12-29 HR HR20100626T patent/HRP20100626T1/hr unknown
- 2004-12-29 JP JP2006547579A patent/JP4949852B2/ja not_active Expired - Lifetime
- 2004-12-29 AU AU2004312546A patent/AU2004312546B2/en not_active Expired
- 2004-12-29 EP EP10158740A patent/EP2204374B1/en not_active Expired - Lifetime
- 2004-12-29 KR KR1020127013492A patent/KR20120080240A/ko not_active Ceased
- 2004-12-29 SI SI200431534T patent/SI1716162T1/sl unknown
- 2004-12-29 PL PL380828A patent/PL212403B1/pl unknown
2005
- 2005-06-29 US US11/170,325 patent/US20060046981A1/en not_active Abandoned
- 2005-06-29 US US11/170,247 patent/US20060030545A1/en not_active Abandoned
2006
- 2006-06-19 IL IL176407A patent/IL176407A/en active IP Right Grant
- 2006-06-21 IS IS8516A patent/IS2994B/is unknown
- 2006-07-21 ZA ZA2006/06049A patent/ZA200606049B/en unknown
- 2006-07-28 NO NO20063479A patent/NO338001B1/no unknown
- 2006-07-31 KR KR1020067015535A patent/KR101214257B1/ko not_active Expired - Lifetime
2009
- 2009-02-18 US US12/388,295 patent/US8088754B2/en not_active Expired - Lifetime
- 2009-05-05 US US12/436,004 patent/US8268802B2/en not_active Expired - Lifetime
2010
- 2010-11-17 CY CY20101101036T patent/CY1111050T1/el unknown
2011
- 2011-01-13 AU AU2011200141A patent/AU2011200141B2/en not_active Expired
- 2011-02-25 JP JP2011040828A patent/JP2011137029A/ja not_active Withdrawn
2012
- 2012-09-04 HR HRP20120699TT patent/HRP20120699T1/hr unknown
- 2012-09-10 CY CY20121100813T patent/CY1113103T1/el unknown
2015
- 2015-05-18 NO NO20150615A patent/NO338040B1/no unknown

Also Published As

Publication number	Publication date
CA2550222A1 (en)	2005-07-21
PL380828A1 (pl)	2007-03-19
ES2389602T3 (es)	2012-10-29
EA011304B1 (ru)	2009-02-27
CY1111050T1 (el)	2015-06-11
AP2006003675A0 (en)	2006-08-31
EP2204374A1 (en)	2010-07-07
WO2005066189A1 (en)	2005-07-21
CY1113103T1 (el)	2016-04-13
BRPI0418251C1 (pt)	2021-05-25
BRPI0418251B1 (pt)	2019-09-24
JP2007517065A (ja)	2007-06-28
KR20060129360A (ko)	2006-12-15
NO20150615L (no)	2005-07-01
IL176407A (en)	2012-12-31
ATE478082T1 (de)	2010-09-15
US20090291922A1 (en)	2009-11-26
BRPI0418251A (pt)	2007-04-17
HK1097276A1 (en)	2007-06-22
RS52433B (sr)	2013-02-28
CN101816664B (zh)	2012-04-18
AU2004312546B2 (en)	2010-10-14
EA200601263A1 (ru)	2006-12-29
EP1716162A1 (en)	2006-11-02
ES2350983T3 (es)	2011-01-28
HK1146061A1 (en)	2011-05-13
EP2204374B1 (en)	2012-06-13
US8088754B2 (en)	2012-01-03
US20050222090A1 (en)	2005-10-06
PT1716162E (pt)	2010-11-24
SI2204374T1 (sl)	2012-09-28
US20060046981A1 (en)	2006-03-02
DK1716162T3 (da)	2011-01-10
AU2004312546A1 (en)	2005-07-21
CA2550222C (en)	2013-05-28
CN1950383A (zh)	2007-04-18
NO338040B1 (no)	2016-07-25
DK2204374T3 (da)	2012-09-10
EP1716162B1 (en)	2010-08-18
US7553825B2 (en)	2009-06-30
PL212403B1 (pl)	2012-09-28
US20060030545A1 (en)	2006-02-09
JP4949852B2 (ja)	2012-06-13
AU2011200141B2 (en)	2012-02-16
BRPI0418251B8 (pt)	2019-10-08
KR101214257B1 (ko)	2012-12-21
US8268802B2 (en)	2012-09-18
KR20120080240A (ko)	2012-07-16
CN1950383B (zh)	2010-06-09
IL176407A0 (en)	2006-10-05
HRP20100626T1 (hr)	2011-03-31
JP2011137029A (ja)	2011-07-14
HRP20060254A2 (en)	2006-10-31
PT2204374E (pt)	2012-09-17
AP2212A (en)	2011-03-01
PL1716162T3 (pl)	2011-02-28
PL2204374T3 (pl)	2012-11-30
IS8516A (is)	2006-06-21
US20090149400A1 (en)	2009-06-11
NO338001B1 (no)	2016-07-18
ZA200606049B (en)	2008-01-08
NO20063479L (no)	2006-10-02
RS51476B (sr)	2011-04-30
SG149075A1 (en)	2009-01-29
DE602004028763D1 (de)	2010-09-30
CN101816664A (zh)	2010-09-01
NZ548771A (en)	2010-05-28
HRP20120699T1 (hr)	2012-09-30
AU2011200141A1 (en)	2011-02-03
SI1716162T1 (sl)	2010-12-31

Publication	Publication Date	Title
IS8516A (is)	2006-06-21	Fosfónöt, monofosfónamidöt, bisfosfónamidöt til meðhöndlunar á veirusjúkdómum
IS2722B (is)	2011-03-15	1, 2, 3, 4- Tetrasetin indól til meðhöndlunar á öndunarfærasjúkdómum
DK1633726T3 (da)	2011-03-28	Pyrimidinderivater, der er egnede til behandling af CRTH2-formidlede sygdomme
AP2378A (en)	2012-03-08	Sulfonamide derivatives for the treatment of diseases.
DK1478358T3 (da)	2013-10-07	Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
DK1720571T3 (da)	2012-09-03	Fremgangsmåde til behandling af hæmolytisk sygdom
DK1663287T3 (da)	2009-11-09	Anvendelse af modificerede cyclosporiner til behandling af HCV-sygdomme
DK1556342T3 (da)	2008-07-21	Phenethanolaminderivat til behandling af respiratoriske sygdomme
LT2878297T (lt)	2020-07-10	Medikamentai, skirti fibrozinių ligų gydymui arba prevencijai
IS7755A (is)	2005-03-17	Aðferð við framleiðslu á (S,S)-cis-2-benshýdríl-3-bensýlamínókínuklídín
AP2359A (en)	2012-01-30	Sulfonamide derivatives for the treatment of diseases.
NO20053077D0 (no)	2005-06-23	Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
NL1029015A1 (nl)	2005-11-15	Therapeutische verbindingen.
IS8142A (is)	2005-11-23	Læknislyf gagnleg til meðferðar á verkjum
IS7137A (is)	2004-01-30	Samsett meðferð til meðhöndlunar á krabbameini
ATE443704T1 (de)	2009-10-15	Pyridopyrimidinone zur behandlung von krebserkrankungen
IL175535A (en)	2016-03-31	Compositions for treatment of neurodegenerative diseases
IS7163A (is)	2004-02-26	Aðferðir til meðhöndlunar á lungnasjúkdómi
FI20030383A0 (fi)	2003-03-14	Menetelmä katalyytin valmistamiseksi
DK1687297T3 (da)	2014-09-22	Triazindimerer til behandling af autoimmunsygdomme
NO20052471D0 (no)	2005-05-23	Fremgangsmate for fremstilling av 3-metyltiopropanal.
ITMI20030346A1 (it)	2004-08-28	Procedimento per la produzione di mesitilene.
NO20054034D0 (no)	2005-08-30	Fremgangsmate for behandling av hypotyroidisme.
NO20053189D0 (no)	2005-06-29	HVC-kombinasjonsterapi.
DK1474415T3 (da)	2011-11-21	1-phenyl-2-heteroaryl-substituerede benzimidazolderivater, deres anvendelse til fremstilling af lægemidler til behandling af immunologiske sygdomme